One Case of Acute Pulmonary Embolism Induced by Combination of Mirtazapine and Clomipramine Tablets

Abstract

CLC Number:

R994.11

LIU Yan-hui, YANG Su-qiao, WANG Ying, CUI Xiang-li. One Case of Acute Pulmonary Embolism Induced by Combination of Mirtazapine and Clomipramine Tablets[J]. Chinese Journal of Pharmacovigilance, 2018, 15(6): 375-376.

References

[1] Chan C M, Woods C, Shorr A F.The validation and reproducibility of the pulmonary embolism severity index[J]. Journal of Thrombosis& Haemostasis Jth, 2010, 8(7):1509-1514.
[2] 徐庆, 徐薇. 14例急性肺栓塞原因分析[J]. 心脑血管病防治, 2010, 10(5):393-394.
[3] 郑晓圆, 刘瑞, 吕娟,等. 炔雌醇环丙孕酮片致肺栓塞1例[J]. 中国药物警戒, 2017, 14(6):381-382.
[4] Wu C S, Chang C M, Chen C Y, et al.Association between antidepressants and venous thromboembolism in Taiwan[J]. Journal of Clinical Psychopharmacology, 2013, 33(1):31-37.
[5] 杜文民, 王永铭, 程能能. 药品不良反应的判定与其研究方法(续完)[J]. 中国药物警戒, 2005, 2(1):11-13.
[6] Jick S S, Li L.Antidepressant drug use and risk of venous thromboembolism[J]. Pharmacotherapy the Journal of Human Pharmacology& Drug Therapy, 2008, 28(2):144-150.
[7] Parkin L, Skegg D C, Herbison G P, et al.Psychotropic drugs and fatal pulmonary embolism[J].Pharmacoepidemiology & Drug Safety, 2003, 12(8):647-652.
[8] Zink M, Knopf U, Argiriou S, et al.A case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone[J]. Journal of Clinical Psychiatry, 2006, 67(5):835.
[9] Tam D W H. Sudden death from pulmonary hypertension in a depressed patient: A case report[J]. Hong Kong Journal of Psychiatry, 2009, 19(4):155-158.
[10] Le M J, Bailey D, Baker G B.Selective serotonin reuptake inhibitors and myocardial infarction[J]. Circulation, 2001, 104(16):1894-1898.
[11] Meijer W E E, Heerdink E R, Nolen W A, et al. Association of Risk of Abnormal Bleeding With Degree of Serotonin Reuptake Inhibition by Antidepressants[J]. Archives of Internal Medicine, 2004, 164(21):2367-2370.
[12] 中华医学会心血管病学分会肺血管病学组. 急性肺栓塞诊断与治疗中国专家共识(2015)[J]. 中华心血管病杂志, 2016, 44(3):197-211.

[1]	SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131.
[2]	ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136.
[3]	BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140.
[4]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[5]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[6]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[7]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[8]	WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
[9]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[10]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[11]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[12]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[13]	LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
[14]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[15]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.